Kuninobu Kanai
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 8
- Cancer Cells and Metastasis 5
-
- Occupational and environmental lung diseases 5
- Lung Cancer Treatments and Mutations 5
- Respiratory and Cough-Related Research 2
- Pleural and Pulmonary Diseases 2
-
- Cancer Research and Treatments 6
-
- Asthma and respiratory diseases 3
- Co-authors
- Masanori NakanishiKeiichiro AkamatsuNobuyuki YamamotoHiroaki AkamatsuAtsushi HayataYasuhiro KohNahomi TokudomeHiroki Ueda
- Journals
- Journal of Clinical Oncology (1 paper)SHILAP Revista de lepidopterología (1 paper)The Journal of Immunology (1 paper)
- Partner nations
- JapanUnited StatesNorway
In The Last Decade
Kuninobu Kanai
22 papers receiving 618 citations
Peers
Comparison fields: 5 of 70
- Oncology 435
- Pulmonary and Respiratory Medicine 316
- Immunology 98
- Cancer Research 61
- Microbiology 3
Countries citing papers authored by Kuninobu Kanai
This map shows the geographic impact of Kuninobu Kanai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kuninobu Kanai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kuninobu Kanai more than expected).
Fields of papers citing papers by Kuninobu Kanai
This network shows the impact of papers produced by Kuninobu Kanai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kuninobu Kanai. The network helps show where Kuninobu Kanai may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kuninobu Kanai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 3 | |
| 2 | 2023 | 3 | |
| 3 | 2020 | 1 | |
| 4 | 2020 | 2 | |
| 5 | 2020 | 17 | |
| 6 | 2020 | 16 | |
| 7 | 2019 | 47 | |
| 8 | 2019 | 37 | |
| 9 | 2019 | 1 | |
| 10 | 2018 | 4 | |
| 11 | 2018 | 6 | |
| 12 | 2017 | 36 | |
| 13 | 2017 | 310 | |
| 14 | 2017 | 2 | |
| 15 | 2016 | 0 | |
| 16 | 2015 | 31 | |
| 17 | 2015 | 50 | |
| 18 | 2014 | 19 | |
| 19 | 2014 | 23 | |
| 20 | 1962 | 1 |
About Kuninobu Kanai
Kuninobu Kanai is a scholar working on Microbiology, Biotechnology and Pulmonary and Respiratory Medicine, having authored 24 papers that have together received 622 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Cancer Research and Treatments (6 papers), Cancer Cells and Metastasis (5 papers), Occupational and environmental lung diseases (5 papers), Lung Cancer Treatments and Mutations (5 papers), Asthma and respiratory diseases (3 papers), Respiratory and Cough-Related Research (2 papers) and Pleural and Pulmonary Diseases (2 papers). The work is most often cited by research in Oncology (435 citations), Pulmonary and Respiratory Medicine (316 citations) and Immunology (98 citations). Kuninobu Kanai has collaborated with scholars based in Japan, United States and Norway. Frequent co-authors include Masanori Nakanishi, Keiichiro Akamatsu, Nobuyuki Yamamoto, Hiroaki Akamatsu, Atsushi Hayata, Yasuhiro Koh, Nahomi Tokudome, Hiroki Ueda, Koichi Sato and Eriko Murakami. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.